Ocular Therapeutix (OCUL) Convertible Debt (2019 - 2023)

Ocular Therapeutix has reported Convertible Debt for 5 years, with the latest figure at $9.1 million in Q4 2023.

• For the quarter ending Q4 2023, Convertible Debt fell 68.21% year-over-year to $9.1 million; the trailing twelve-month figure through Dec 2023 stood at $9.1 million (down 68.21% YoY), and the FY2023 full-year result was $9.1 million, down 68.21% from the prior year.
• Convertible Debt for Q4 2023 stood at $9.1 million, up from $8.8 million in the prior quarter.
• The five-year high for Convertible Debt was $30.0 million in Q2 2023, with the low at $8.8 million in Q3 2023.
• Average Convertible Debt over 5 years is $24.3 million, with a median of $25.3 million recorded in 2020.
• Year-over-year, Convertible Debt grew 10.27% in 2020 and tumbled 68.87% in 2023.
• Tracing OCUL's Convertible Debt over 5 years: stood at $24.3 million in 2019, then grew by 0.01% to $24.3 million in 2020, then advanced by 8.75% to $26.4 million in 2021, then climbed by 8.75% to $28.7 million in 2022, then tumbled by 68.21% to $9.1 million in 2023.
• The last three Convertible Debt figures came in at $9.1 million (Q4 2023), $8.8 million (Q3 2023), and $30.0 million (Q2 2023), per Business Quant data.

Peer Comparison